Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

NCT06055985 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT06055985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06055985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2023
Completion date
April 11, 2025
Enrollment
207 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease